Keyphrases
Eastern Cooperative Oncology Group
100%
Twice Daily
100%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
100%
Thoracic Radiotherapy
100%
Alternating Chemotherapy
100%
Chemotherapy
83%
Etoposide
50%
Cisplatin
33%
Complete Response
33%
Confidence Interval
16%
Day Range
16%
Sepsis
16%
Neutropenia
16%
Cyclophosphamide
16%
Nineteen
16%
Leukopenia
16%
Life-threatening
16%
Median Survival
16%
Partial Response
16%
Radiotherapy Dose
16%
Treatment Cycle
16%
Consecutive Days
16%
Progression-free Survival
16%
Esophagitis
16%
Overall Response Rate
16%
Pulmonary Fibrosis
16%
Small Cell Lung Cancer
16%
Lung Cancer Patients
16%
Concurrent Chemotherapy
16%
Adult Respiratory Distress Syndrome
16%
Induction Treatment
16%
Induction Regimen
16%
Prophylactic Cranial Irradiation
16%
Nursing and Health Professions
Radiotherapy
100%
Pilot Study
100%
Small Cell Lung Cancer
100%
Etoposide
50%
Cisplatin
33%
Confidence Interval
16%
Sepsis
16%
Cyclophosphamide
16%
Leukopenia
16%
Neutropenia
16%
Adult Respiratory Distress Syndrome
16%
Progression Free Survival
16%
Esophagitis
16%
Skull Irradiation
16%
Lung Fibrosis
16%
Medicine and Dentistry
Radiation Therapy
100%
Oncology
100%
Small Cell Lung Cancer
100%
Etoposide
50%
Cisplatin
33%
Neutropenia
16%
Sepsis
16%
Acute Respiratory Distress Syndrome
16%
Leukopenia
16%
Cyclophosphamide
16%
Progression Free Survival
16%
Esophagitis
16%
Pulmonary Fibrosis
16%
Prophylactic Cranial Irradiation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Small Cell Lung Cancer
100%
Etoposide
42%
Cisplatin
28%
Adult Respiratory Distress Syndrome
14%
Neutropenia
14%
Cyclophosphamide
14%
Progression Free Survival
14%
Sepsis
14%
Leukopenia
14%
Esophagitis
14%
Lung Fibrosis
14%
Agricultural and Biological Sciences
Confidence Interval
100%
Cyclophosphamide
100%
Acute Respiratory Distress Syndrome
100%
Immunology and Microbiology
Cyclophosphamide
100%
Esophagitis
100%
Progression Free Survival
100%